Recent Investment Analysts’ Ratings Changes for Acumen Pharmaceuticals (ABOS)

A number of research firms have changed their ratings and price targets for Acumen Pharmaceuticals (NASDAQ: ABOS):

• 11/2/2026 – Acumen Pharmaceuticals had its price target lowered by BTIG Research to $1.00. They now have a “buy” rating on the stock.
• 11/2/2026 – Acumen Pharmaceuticals was downgraded by Bank of America from “buy” to “underperform”. They now have a $1.00 price target on the stock.
• 10/30/2026 – Acumen Pharmaceuticals was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 10/30/2026 – Acumen Pharmaceuticals was downgraded by Cantor Fitzgerald from “strong-buy” to “strong sell”.
• 10/30/2026 – Acumen Pharmaceuticals was downgraded by Citigroup from “buy” to “hold”. They now have a $1.00 price target on the stock.
• 10/30/2026 – Acumen Pharmaceuticals was downgraded by Stifel Nicolaus from “buy” to “hold”. They now have a $1.00 price target on the stock.
• 10/17/2026 – Acumen Pharmaceuticals was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 10/2/2026 – Acumen Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/17/2026 – Acumen Pharmaceuticals had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 9/16/2026 – Acumen Pharmaceuticals had its “buy” rating reaffirmed by BTIG Research. They now have a $8.00 price target on the stock.
• 9/15/2026 – Acumen Pharmaceuticals had its price target raised by Citigroup from $4.00 to $5.00. They now have a “buy” rating on the stock.

Acumen Pharmaceuticals Stock Down 2.8%

Shares of NASDAQ:ABOS traded down $0.01 on Tuesday, reaching $0.23. The company had a trading volume of 5,195,847 shares, compared to its average volume of 1,085,464. The firm has a market capitalization of $16.85 million, a PE ratio of -0.15 and a beta of 0.33. The company has a current ratio of 1.89, a quick ratio of 2.47 and a debt-to-equity ratio of 0.17. Acumen Pharmaceuticals, Inc. has a 52-week low of $0.20 and a 52-week high of $3.60. The firm’s 50 day simple moving average is $2.35 and its 200-day simple moving average is $2.49.

Acumen Pharmaceuticals (NASDAQ:ABOS) last issued its quarterly earnings data on Monday, October 26th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. As a group, analysts expect that Acumen Pharmaceuticals, Inc. will post -1.51 earnings per share for the current fiscal year.

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer’s disease and other neurodegenerative disorders. The company’s research centers on amyloid beta oligomers, toxic protein assemblies that Acumen believes contribute to the development and progression of Alzheimer’s disease.

Acumen’s lead product candidate is sabirnetug, also known as ACU193, an investigational humanized monoclonal antibody designed to selectively target soluble amyloid beta oligomers.